Litigation Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-03-04 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:1 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | Plaintiff | Referred To | Christopher J. Burke |
| Parties | VYTACERA BIO, LLC | ||
| Patents | 9,775,913 | ||
| Attorneys | Richard Juang | ||
| Firms | Stamoulis & Weinblatt LLC | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Vytacera Bio, LLC v. CytomX Therapeutics, Inc.
The biologic drug covered by the patent cited in this case is ⤷ Try a Trial .
Details for Vytacera Bio, LLC v. CytomX Therapeutics, Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-03-04 | 1 | Complaint | United States patent nos. 8,809,504 (“the ’504 patent”) and 9,775,913 (“the ’913 patent) (collectively…claimed in the ’504 patent. United States Patent No. 9,775,913 27. … U.S. Patent No. 9,775,913, entitled “Method of site-specific activation of an antibody by a protease… Count II- Infringement of United States Patent No. 9,775,913 120. The allegations set forth…license the ’504 patent and the patent application that led to the issuance of the ’913 patent. 69 | External link to document |
| 2021-10-07 | 130 | Report and Recommendations | two patents-in-suit: United States Patent Nos. 8,809,504 (the “'504 patent”) and 9,775,913 (the…the “'913 patent” and collectively with the '504 patent, the “patents-in-suit”). (See D.I…x27;504 patent, and claims 1 and 22 of the '913 patent. Claim 1 of the '504 patent is representative…it owns the rights to the '504 patent and the '913 patent, (id. at ¶¶ 25, 32). CytomX is a…hereinafter, “'504 patent”) Abstract; id., ex. 2 (hereinafter, “'913 patent”), Abstract) The & | External link to document |
| 2022-05-09 | 155 | Order - -Memorandum and Order | terms in U.S. Patent Nos. 8,809,504 (the “’504 patent”) and 9,775,913 (the “’913 patent”); WHEREAS… 1 In the ’913 patent, the “biologically active agent” is an “antibody.” (’913 patent cls. 1, 22) There…antibody” of the ’913 patent is a “biologically active agent” as described in the patents, and the Court’s …explicit definition of the RD term in the patents.”) (citing ’504 patent at 6:5-7) 5 The Court finds it…term “recognition domain” in the ’504 and ’913 patents; WHEREAS, on April 7, 2022, CytomX objected | External link to document |
| 2023-10-30 | 178 | Report and Recommendations | States Patent No. 8,809,504 (the “'504 patent”) and United States Patent No. 9,775,913 (the “… “'913 patent”) (together with the '504 patent, the “patents-in-suit”). (D.I. 1 at ¶¶ 74…of 12 PageID #: 4090 '913 patent. (Id.) The patents-in-suit cover molecules inhibiting biologically…claims of the patents-in-suit, but the parties agree that claim 1 of the '504 patent (“claim 1”)…infringes a patent, then it cannot articulate how or why a challenged claim of patent infringement | External link to document |
| 2020-03-04 | 3 | Patent/Trademark Report to Commissioner of Patents | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,809,504 B2 ;US 9,775,913 B2. (sam)… 4 March 2020 1:20-cv-00333 Patent Plaintiff District Court, D. Delaware | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
